Acuvi: Preparing for a Stronger H2 - Redeye

Redeye expected a bit more in terms of top-line growth in Q2, which was softer than we have seen recently. Q2 sales grew by 14% proforma (vs. Q1’22 of 31%). Adjusted EBITDA was quite modest but still in positive territory. Business activity is high and Acuvi is preparing for a stronger second half of 2022. Our positive view on the case is intact, but our forecast adjustments have some negative impact on valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/854036/acuvi-preparing-for-a-stronger-h2?utm_source=finwire&utm_medium=RSS